ClinicalTrials.gg

Program

Edaravone

Also written as “MT-1186”, “MCI-186” and “Continuous infusion high-dose MCI-186”.

Its studies are mostly in Amyotrophic Lateral Sclerosis · Ischemic Stroke · Cerebral Infarction · Renal Insufficiency · Ischemia, led by 4 companies.

Furthest: phase 4, since Sep 12, 200526 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shionogi230 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Jiangsu HengRui Medicine10 open or runningphase 1since Jul 16, 2025Jul 16, 2025none ahead
Nanjing Yoko Biomedical10 open or runningphase 1since Dec 17, 2019Dec 17, 2019none ahead
Shanghai Auzone Biological Technology10 open or runningphase 1since Oct 16, 2023Oct 16, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Sep 12, 2005.

  1. Aug 27, 2018Phase 1 study in Severe Hepatic ImpairmentShionogi · NCT03664544 · 12 enrolled · Czechia, Hungary, Slovakia
  2. Jul 10, 2019Phase 1 study in Healthy Adult SubjectsShionogi · NCT04029090 · 27 enrolled · Japan
  3. Nov 13, 2019Phase 3 study in ALSShionogi · NCT04165824 · 185 enrolled · United States, Canada, France and more
  4. Nov 22, 2019Phase 1 study in Japanese Patients With ALSShionogi · NCT04176224 · 9 enrolled · Japan
  5. Dec 17, 2019Nanjing Yoko Biomedical's first study: phase 1 study in Drug-drug InteractionNew to Nanjing Yoko BiomedicalNanjing Yoko Biomedical · NCT04218513 · 24 enrolled · China
  6. Jan 23, 2020Phase 1 study in Japanese Patients With ALSShionogi · NCT04254913 · 6 enrolled · Japan
  7. Jul 17, 20203 phase 1 studies in Healthy Adult SubjectsShionogi · NCT04481789, NCT04481750, NCT04493281
  8. Sep 23, 20202 phase 3 studiesShionogi · NCT04569084, NCT04577404
  9. Feb 25, 2021Phase 1 study in Healthy Adult SubjectsShionogi · NCT04776135 · 36 enrolled · Japan
  10. Nov 28, 2021Phase 3 study in ALSShionogi · NCT05151471 · 202 enrolled · United States, Canada, Germany and more
  11. Apr 19, 2022Phase 1 study in Healthy Adult SubjectsShionogi · NCT05342597 · 16 enrolled · Japan
  12. Oct 2, 2022Phase 3 study in ALSShionogi · NCT05568615 · 15 enrolled · Japan
  13. Oct 16, 2023Shanghai Auzone Biological Technology's first study: phase 1 study in Healthy Adult SubjectsNew to Shanghai Auzone Biological TechnologyShanghai Auzone Biological Technology · NCT06107205 · 29 enrolled · United States
  14. Jul 16, 2025Jiangsu HengRui Medicine's first study: phase 1 study in Acute Ischemia StrokeNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07083362 · 83 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07083362Acute Ischemia Stroke · China1CompletedJiangsu HengRui MedicineJan 12, 202683
NCT06107205Healthy Adult Subjects · United States1CompletedShanghai Auzone Biological TechnologyDec 14, 202329
NCT05568615ALS · Japan3CompletedShionogiJun 27, 202315
NCT05342597Healthy Adult Subjects · Japan1CompletedShionogiJul 24, 201916
NCT05151471ALS · United States, Canada, Germany and more3TerminatedShionogiSep 29, 2023202
NCT04776135Healthy Adult Subjects · Japan1CompletedShionogiApr 1, 202136
NCT04577404Amyotrophic Lateral Sclerosis · United States, Canada, France and more3CompletedShionogiAug 9, 2023124
NCT04569084ALS · United States, Canada, Germany and more3TerminatedShionogiSep 29, 2023384
NCT04493281Healthy Adult Subjects · Japan1CompletedShionogiApr 21, 201942
NCT04481789Healthy Adult Subjects · Japan1CompletedShionogiDec 20, 201884
NCT04481750Healthy Adult Subjects · Japan1CompletedShionogiAug 3, 201874
NCT04254913Japanese Patients With ALS · Japan1CompletedShionogiApr 16, 20206
NCT04218513Drug-drug Interaction · China1CompletedNanjing Yoko BiomedicalMay 31, 201924
NCT04176224Japanese Patients With ALS · Japan1CompletedShionogiSep 4, 20199
NCT04165824ALS · United States, Canada, France and more3CompletedShionogiOct 7, 2021185
NCT04029090Healthy Adult Subjects · Japan1CompletedShionogiOct 20, 201827
NCT03664544Severe Hepatic Impairment · Czechia, Hungary, Slovakia1CompletedShionogiMar 25, 201912
NCT03346538Ischemic Stroke · Japan2TerminatedShionogiMay 14, 201817
NCT03289234Hepatic Impairment · Japan1CompletedShionogiJul 20, 201822
NCT03289208Renal Insufficiency · Japan1CompletedShionogiApr 16, 201830
NCT01492686Amyotrophic Lateral Sclerosis · Japan3CompletedShionogiSep 30, 2014137
NCT00821821Ischemic Stroke · Finland, Netherlands, United Kingdom2CompletedShionogiNov 30, 201036
NCT00424463Amyotrophic Lateral Sclerosis · Japan3CompletedShionogiMay 31, 2009181
NCT00415519Amyotrophic Lateral Sclerosis3CompletedShionogiJul 31, 200825
NCT00330681Amyotrophic Lateral Sclerosis3CompletedShionogiSep 30, 2008206
NCT00200356Cerebral Infarction4CompletedShionogiOct 31, 2006401

How it is read

Names in the registry

  • “MT-1186”, 12 entries
  • “MCI-186”, 10 entries
  • “Edaravone”, 1 entry
  • “Continuous infusion high-dose MCI-186”, 1 entry
  • “Continuous infusion low-dose MCI-186”, 1 entry

Codes read as this program: MT1186, MCI186.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.